首都医科大学学报 ›› 2021, Vol. 42 ›› Issue (3): 404-407.doi: 10.3969/j.issn.1006-7795.2021.03.010

• 精神疾病中西医结合治疗 • 上一篇    下一篇

石珍安神颗粒改善精神分裂症前驱期患者认知损害的临床观察

宁艳哲, 朱虹, 宋楠, 郑思思, 李自艳, 李佳佳, 马睿, 贾竑晓*   

  1. 首都医科大学附属北京安定医院国家精神心理疾病临床研究中心 精神疾病诊断与治疗北京市重点实验室,北京 100088
  • 收稿日期:2021-03-15 出版日期:2021-06-21 发布日期:2021-06-16
  • 通讯作者: *E-mail:jhxlj@vip.163.com
  • 基金资助:
    北京市自然科学基金(7212050),首都卫生发展科研专项(2018-1-2122,2020-4-2126),北京市医院管理中心登峰人才(DFL20191901), 北京市医院管理中心临床医学发展专项(ZYLX202129),北京市中医药科技发展资金项目(QN2018-27), 北京市优秀人才培养资助项目(2018000021469G292)。

A preliminary study on efficacy for Shi-zhen-an-shen granules on cognitive impairments in prodromal schizophrenia

Ning Yanzhe, Zhu Hong, Song Nan, Zheng Sisi, Li Ziyan, Li Jiajia, Ma Rui, Jia Hongxiao*   

  1. The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University & The Advanced Innovation Center for Human Brain Protection, Beijing 100088,China
  • Received:2021-03-15 Online:2021-06-21 Published:2021-06-16
  • Contact: *E-mail:jhxlj@vip.163.com
  • Supported by:
    Natural Science Foundation of Beijing (7212050), Capital’s Funds for Health Improvement and Research (2018-1-2122,2020-4-2126), Dengfeng Talents of Beijing Hospital Management Center(DFL20191901), Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (ZYLX202129), Chinese Medicine Science and Technology Development Found of Beijing (QN2018-27),Talents Training Fund of Beijing(2018000021469G292).

摘要: 目的 研究石珍安神颗粒治疗对精神分裂症前驱期患者认知功能的改善作用。方法 纳入 60 例受试者采用数字法随机分为治疗组和对照组,治疗组予石珍安神颗粒和阿立哌唑安慰剂,对照组予阿立哌唑和石珍安神颗粒安慰剂。所有受试者在治疗前和治疗28 d后进行认知功能评估,包括连线测验(Trail Making Test A, TMTA)、霍普金斯词语学习测验-修订版(Hopkins Verbal Learning Test-revised, HVLT-R)、简易视觉空间记忆测验-修订版 (Brief Visuospatial Memory Test Revised, BVMT-R) 、Stroop 色词测验(Stroop Color-word Test ,SCWT)和持续操作测验(Continuous Performance Test, CPT),并进行统计分析。结果 两组在所有认知功能评价指标的组间主效应差异均无统计学意义(P>0.05),两组在TMTA、HVLT-R、BVMT-R、Stroop词测验、SCWT和CPT的时间主效应差异均有统计学意义(P<0.05),两组仅在SCWT和CPT上存在时间与组间的交互作用(P<0.05)。治疗组在所有认知功能评价指标上治疗后与治疗前相比,差异均有统计学意义(P<0.05);对照组仅在HVLT-R、BVMT-R、SCWT和CPT上治疗后与治疗前相比,差异有统计学意义(P<0.05)。结论 石珍安神颗粒在改善精神分裂前驱期的认知损害方面与阿立哌唑作用相似,但治疗前后多数指标的变化程度相对优于阿立哌唑。

关键词: 石珍安神颗粒, 精神分裂症前驱期, 认知损害

Abstract: Objective To investigate efficacy for Shi-zhen-an-shen (SZAS) granules on cognitive impairments in prodromal schizophrenia. Methods A total of 60 eligible participants were randomly assigned to either the treatment group or the control group in a ratio of 1∶1. The participants in the treatment group received SZAS and the placebo of aripiprazole, the control group received placebo of SZAS and aripiprazole. The treatment course had lasted for 4 weeks. Outcome measurements included Trail Making Test A (TMTA), Hopkins Verbal Learning Test-Revised (HVLT-R), Brief Visuospatial Memory Test Revised (BVMT-R),Continuous Performance Test (CPT), and Stroop Color-Word Test (SCWT). Results There were no significant group effects on all cognitive assessments between the two groups. The time effects on TMTA,HVLT-R,BVMT-R,Stroop-word test,SCWT and CPT showed significant differences between the two groups. The SCWT and CPT showed significant interactive effects. Further analysis indicated significant changes on all cognitive assessments in the treatment group after 4-weeks therapy in comparison with baseline, while only HVLT-R, BVMT-R, SCWT and CPT showed significant changes in the control group after 4-weeks treatment. Conclusion Compared with aripiprazole, the SZAS could improve cognitive impairment more widely. Longer time treatment may support that the SZAS is better than aripiprazole on improving cognitive impairments.

Key words: Shi-zhen-an-shen granules, prodromal schizophrenia, cognitive impairment

中图分类号: